Compare IVDA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVDA | LGVN |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 21.4M |
| IPO Year | 2015 | 2021 |
| Metric | IVDA | LGVN |
|---|---|---|
| Price | $0.31 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 363.2K | 145.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.38 | 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,468,279.00 | $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 132.98 | N/A |
| 52 Week Low | $0.21 | $0.48 |
| 52 Week High | $2.24 | $7.60 |
| Indicator | IVDA | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 40.53 |
| Support Level | $0.27 | $0.61 |
| Resistance Level | $0.33 | $7.45 |
| Average True Range (ATR) | 0.02 | 0.42 |
| MACD | 0.00 | -0.58 |
| Stochastic Oscillator | 45.70 | 9.24 |
Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.